Veterans’ RightsAn independent resource for veterans
← All decisions
Remanded (sent back)

The Veteran's herpes simplex requires constant or near-constant systemic therapy, and the Board has granted a rating of 60 percent for this condition. The case is remanded for further consideration regarding TDIU.

The deciding factor: The Veteran's herpes simplex required constant or near-constant systemic therapy (Valacyclovir) during the past 12-month period, which meets the criteria for a 60 percent rating under the new General Rating Formula for the Skin.

Claimed conditions
Herpes Simplex
How they argued it
Direct service connection
Exposure basis
None
Rating assigned
60%
Decision date
December 29, 2021
Citation
21077294

This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Look up the original decision on VA.gov (opens in a new tab) using citation 21077294.

What this means for you

A remand is not a loss. The Board sent the case back for more development — often a new exam or missing records — before making a final decision. Many remands later end in a grant, and the decision spells out exactly what the Board wanted to see.

What you can do next

Related decisions

Other Board decisions on a similar condition or argued the same way.

Free starter guide for your own claim

Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.

We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.

We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.

This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.